Vertex has been developing inhibitors to the NaV1.8 sodium channel for many years and previously abandoned other candidates because they were not selective enough for the target and inhibited ...
Scotiabank analyst Greg Harrison maintained a Buy rating on Geron (GERN – Research Report) today and set a price target of $6.00. The ...
Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...
Up until a couple of decades ago, hair loss was something that guys just had to accept and take in stride. Then came ...
RYTELOâ„¢ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent ...
Vertex announced in April that the FDA had ... February 2024 with the backing of $135 million and its lead oral NaV1.8 inhibitor asset that is currently in a Phase 1 trial to treat acute and ...
Objective To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Examples include golimumab, an anti-tumour necrosis factor antibody, or baricitinib, a Janus kinase inhibitor, for which continuous administration could also prevent—to a large extent—the reduction in ...
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback